Home | Medical Dictionary | Contact Us         
 
 
  • About
    Cedars-Sinai
  • Careers at
    Cedars-Sinai
  • Giving
    & Support
  • Health
    Conditions
  • Healthcare
    Professionals
  • Patients
    & Visitors
  • Programs
    & Services
  • Quality
    Measures
  • Research &
    Education
  • Healthcare Professionals
  • S. Mark Taper Foundation Imaging Center
  • Cardiac Imaging
  • Case of the Month
  • Case of the Month Archive
  • Clinical Trials
  • 99mTc-NC100697 and SPECT
  • CT-STAT
  • Cardiovascular MRI Database
  • Cervical Cancer Study
  • Diffusion Tensor MR
  • EISNER Study 1
  • EISNER Study 2R
  • EISNER Study 4- Database Project
  • FDG-PET/CT Study
  • GE I-mIBG Study
  • Nuclear Cardiology Database Study
  • Parkinsonian Syndrome Study
  • RF Ablation Study
  • Scintigraphic Swallow Evaluation
  • Statins Study
  • Directions and Parking
  • Exam Information Sheets
  • For Patients
  • Imaging Newsletter
  • Imaging Technologies
  • Interventional Neuroradiology
  • Interventional Radiology
  • Neuroradiology
  • Neurovascular Team
  • News
  • Online Film/Image Copy Request
  • Our Expert Team
  • PET/CT Imaging
  • Physicians by Specialty
  • Preventive and Wellness Screenings
  • Referral Pads
  • Residency and Fellowship Programs
  • Web/VS User's Guide for Images
 
RF Ablation in Patients with Liver Cancer and Hepatic Cirrhosis

Protocol Title:
Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients

Working Title:
The purpose of this research is to determine if percutaneous radiofrequency ablation (RFA) of the liver to treat hepatocellular carcinoma (HCC) in patients with cirrhosis is at least as effective as hepatic resection or liver transplantation. This research is also being conducted to estimate the proportion of patients who undergo solitary or repetitive liver RFA treatment sessions whose liver tumors can be controlled with no identifiable tumor present within the liver at 18 months following initiation of therapy. RFA is a therapeutic technique that can eradicate [liver] tumors, can be used in a greater number of patients and can be used to treat tumor recurrences within the liver that occur in the majority of patients.

Principal Investigator:
Peter J. Julien, MD

IRB Approval Number:
8715

Medical Specialty Area:
CT Body Imaging

Condition/Disease:
Hepatocellular Liver Cancer with Cirrhosis

IRB Approval Expiration Date:
01/31/2007

Contact Information:
Rene Siegel
Phone: (310) 423-3398
Send Us a Message
 
Cedars-Sinai Logo

© Copyright 2000-2008 Cedars-Sinai Health System.
All rights reserved.
Privacy Policy Terms and Conditions